An interventional study of Lactobacillus cispatus and placebo in Bacterial Vaginosis, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Zhujiang Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Vaginosis, Bacterial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Vaginosis, Bacterial · China.
Among the 16 studies in Vaginosis, Bacterial with a site in China, this one is the 9th largest by planned enrollment, is one of 2 that started in 2024, is one of 2 with no phase, and was the 8th registered.
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
Browse Vaginosis, Bacterial studies →6 of the 16 studies in Vaginosis, Bacterial with a site in China are open now. Recruiting first, the newest first:
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–50 · Women only
Peking University Shenzhen Hospital · Sites in China
Ages 18–55 · Women only · Healthy volunteers
SPH Sine Pharmaceutical Laboratories Co., Ltd. · Sites in China
Ages 18–55 · Women only
Chengdu Syncor Pharmaceutical Co., Ltd. · Sites in China
Ages 18–50 · Women only
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 120 is above the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Median enrollment 123 across the 16 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 10 most frequent:
Zhujiang Hospital is the lead sponsor of 202 studies on the registry; 96 are open to participants now.
Zhujiang Hospital has 1 study filed under Vaginosis, Bacterial — fewer than ten, so there is no comparison to draw.
4 of the studies in Vaginosis, Bacterial with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04771728Peking University Shenzhen HospitalA Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis | 2026-12-01 |
| NCT07663838Changchun GeneScience Pharmaceutical Co., Ltd.A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) | 2027-01-05 |
| NCT07483671Chengdu Syncor Pharmaceutical Co., Ltd.Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients | 2027-01-24 |
| NCT07888699SPH Sine Pharmaceutical Laboratories Co., Ltd.WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis | 2027-10-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Vaginosis, Bacterial with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study was to explore the efficacy and safety of a new vaginal microbiome transplantation technique, using Lactobacillus cispatus from healthy donors as a treatment of bacterial vaginosis.
The volunteers will be recruited from the women who come to the hospital to do the bacterial vaginosis test. After being informed about the potential risks, each volunteer giving written informed consent will be asked to complete a questionnaire.
Then, posterior fornix of vagina secretions will be taken from each volunteer to perform 16S rRNA gene sequencing microecology assessment , Clue cell detection and amine test.
After 2weeks ,1 month ,3 months,6 months,12 monthssince the entry, each volunteer will be asked to go back to research center to do the same sampling and examination as previously did in entry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10\^9 cfu,5 days
Other: Lactobacillus cispatus
0 cfu,5 days
Other: placebo
10\^9 cfu,5 days
0 cfu,5 days
BV recurrence rate
Primary Outcome Measure
Time frame: month 12
vaginal secretions 16s rRNA gene sequencing
Secondary Outcome Measures
Time frame: 2 weeks,month 1,month 3、month 6、month 12
BV recurrence rate
Secondary Outcome Measures
Time frame: 2 weeks,month 1,month 3、month 6
Started Mar 2024 (actual). Primary completion is estimated for Jul 2025, 15 months after the start.
Of 52 interventional studies with no phase under Vaginosis, Bacterial, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 56. This study's planned 15 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.